Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Not Confirmed
Not Confirmed
10-11 June, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
09-11 June, 2025
Annual Outsourcing in ...Annual Outsourcing in CT
Industry Trade Show
Not Confirmed
10-11 June, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/excipient-market-overview-roquette-announces-restructuring-post-iff-pharma-buyout-who-fda-advance-regulatory-frameworks
21 May 2025
// FIERCE PHARMA
https://www.fiercepharma.com/marketing/csl-behrings-1st-commercial-shows-hizentra-erasing-germ-concerns-primary-immunodeficiency
12 Apr 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/pfizer-backs-out-hemophilia-gene-therapy-csl-hopes-hemgenix-here-stay
20 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/csl-receives-approval-in-japan-for-andembry-garadacimab-subcutaneous-sc-injection-200mg-pens-a-novel-human-anti-activated-factor-xii-monoclonal-antibody-for-the-prevention-of-acute-attacks-of-hereditary-angioedema-hae-302381447.html
13 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/european-commission-approves-csls-andembry-garadacimab-for-the-prevention-of-recurrent-attacks-of-hereditary-angioedema-hae-302375479.html
07 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/csl-behrings-gene-therapy-hemgenix-etranacogene-dezaparvovec-drlb-four-years-post-infusion-data-continue-to-show-sustained-efficacy-and-safety-in-adults-with-hemophilia-b-302371300.html
21 Jan 2025
// PHARMAWEB
https://www.pharmiweb.com/press-release/2025-01-21/first-patients-treated-with-hemgenix-etranacogene-dezaparvovec-gene-therapy-for-haemophilia-b-in-denmark
Inspections and registrations
ABOUT THIS PAGE
CSL Behring is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Water bulk with CEP offered by CSL Behring
Find a price of ISCOMATRIX ADJUVANT bulk offered by CSL Behring